IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i19p12480-d930025.html
   My bibliography  Save this article

The Characteristics and Mortality of Chinese Herbal Medicine Users among Newly Diagnosed Inoperable Huge Hepatocellular Carcinoma (≥10 cm) Patients: A Retrospective Cohort Study with Exploration of Core Herbs

Author

Listed:
  • Shu-Ling Chen

    (Division of Chinese Internal and Pediatric Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, Taoyuan 333, Taiwan)

  • Chia-Ying Ho

    (Division of Chinese Internal and Pediatric Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, Taoyuan 333, Taiwan)

  • Wei-Chun Lin

    (Department of Emergency Medicine, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan)

  • Chao-Wei Lee

    (Division of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
    College of Medicine, Chang Gung University, Guishan, Taoyuan 333, Taiwan)

  • Yu-Chun Chen

    (Department of Family Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan
    School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan
    Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei 112, Taiwan)

  • Jiun-Liang Chen

    (Division of Chinese Internal and Pediatric Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, Taoyuan 333, Taiwan
    School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan)

  • Hsing-Yu Chen

    (Division of Chinese Internal and Pediatric Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, Taoyuan 333, Taiwan
    School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
    Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan)

Abstract

For patients with inoperable huge hepatocellular carcinoma (H-HCC, tumor size ≥10 cm), treatment options are limited. This study aimed to evaluate the characteristics and outcomes of patients with H-HCC who use Chinese herbal medicine (CHM). Multi-institutional cohort data were obtained from the Chang Gung Research Database (CGRD) between 1 January 2002 and 31 December 2018. All patients were followed up for 3 years or until the occurrence of death. Characteristics of CHM users and risk of all-cause mortality were assessed, and core CHMs with potential pharmacologic pathways were explored. Among 1618 patients, clinical features of CHM users (88) and nonusers (1530) were similar except for lower serum α-fetoprotein (AFP) and higher serum albumin levels in CHM users. CHM users had significantly higher 3 year overall survival rates (15.0% vs. 9.7%) and 3 year liver-specific survival rates (13.4% vs. 10.7%), about 3 months longer median survival time, and lower risk of all-cause mortality. Core CHMs were discovered from the prescriptions, including Hedyotis diffusa Willd combined with Scutellaria barbata D.Don, Salvia miltiorrhiza Bunge., Curcuma longa L., Rheum palmatum L., and Astragalus mongholicus Bunge. CHM use appears safe and is possibly beneficial for inoperable H-HCC patients; however, further clinical trials are still required.

Suggested Citation

  • Shu-Ling Chen & Chia-Ying Ho & Wei-Chun Lin & Chao-Wei Lee & Yu-Chun Chen & Jiun-Liang Chen & Hsing-Yu Chen, 2022. "The Characteristics and Mortality of Chinese Herbal Medicine Users among Newly Diagnosed Inoperable Huge Hepatocellular Carcinoma (≥10 cm) Patients: A Retrospective Cohort Study with Exploration of Co," IJERPH, MDPI, vol. 19(19), pages 1-18, September.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:19:p:12480-:d:930025
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/19/12480/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/19/12480/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Alexander C. Huang & Michael A. Postow & Robert J. Orlowski & Rosemarie Mick & Bertram Bengsch & Sasikanth Manne & Wei Xu & Shannon Harmon & Josephine R. Giles & Brandon Wenz & Matthew Adamow & Debora, 2017. "T-cell invigoration to tumour burden ratio associated with anti-PD-1 response," Nature, Nature, vol. 545(7652), pages 60-65, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jianjiao Ni & Xiaofei Wang & Lin Wu & Xinghao Ai & Qian Chu & Chengbo Han & Xiaorong Dong & Yue Zhou & Yechun Pang & Zhengfei Zhu, 2024. "Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    2. Sanjay M. Prakadan & Christopher A. Alvarez-Breckenridge & Samuel C. Markson & Albert E. Kim & Robert H. Klein & Naema Nayyar & Andrew W. Navia & Benjamin M. Kuter & Kellie E. Kolb & Ivanna Bihun & Jo, 2021. "Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    3. Elaine Lai-Han Leung & Run-Ze Li & Xing-Xing Fan & Lily Yan Wang & Yan Wang & Zebo Jiang & Jumin Huang & Hu-Dan Pan & Yue Fan & Hongmei Xu & Feng Wang & Haopeng Rui & Piu Wong & Hermi Sumatoh & Michae, 2023. "Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    4. Ghanizadeh, Mojtaba & Shariatpanahi, Seyed Peyman & Goliaei, Bahram & Rüegg, Curzio, 2021. "Mathematical modeling approach of cancer immunoediting reveals new insights in targeted-therapy and timing plan of cancer treatment," Chaos, Solitons & Fractals, Elsevier, vol. 152(C).
    5. Panayiotis Anastasiou & Christopher Moore & Sareena Rana & Mona Tomaschko & Claire E. Pillsbury & Andrea Castro & Jesse Boumelha & Edurne Mugarza & Sophie Carné Trécesson & Ania Mikolajczak & Cristina, 2024. "Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    6. Jeppe Sejerø Holm & Samuel A. Funt & Annie Borch & Kamilla Kjærgaard Munk & Anne-Mette Bjerregaard & James L. Reading & Colleen Maher & Ashley Regazzi & Phillip Wong & Hikmat Al-Ahmadie & Gopa Iyer & , 2022. "Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    7. Jianming Xu & Yi Li & Qingxia Fan & Yongqian Shu & Lei Yang & Tongjian Cui & Kangsheng Gu & Min Tao & Xiuwen Wang & Chengxu Cui & Nong Xu & Juxiang Xiao & Quanli Gao & Yunpeng Liu & Tao Zhang & Yuxian, 2022. "Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    8. Meghana Pagadala & Timothy J. Sears & Victoria H. Wu & Eva Pérez-Guijarro & Hyo Kim & Andrea Castro & James V. Talwar & Cristian Gonzalez-Colin & Steven Cao & Benjamin J. Schmiedel & Shervin Goudarzi , 2023. "Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    9. David J. Klinke & Audry Fernandez & Wentao Deng & Atefeh Razazan & Habibolla Latifizadeh & Anika C. Pirkey, 2022. "Data-driven learning how oncogenic gene expression locally alters heterocellular networks," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    10. Manuel Rodrigues & Giulia Vanoni & Pierre Loap & Coraline Dubot & Eleonora Timperi & Mathieu Minsat & Louis Bazire & Catherine Durdux & Virginie Fourchotte & Enora Laas & Nicolas Pouget & Zahra Castel, 2023. "Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    11. Bei Li & Guohao Wang & Kai Miao & Aiping Zhang & Liangyu Sun & Xinwang Yu & Josh Haipeng Lei & Lisi Xie & Jie Yan & Wenxi Li & Chu-Xia Deng & Yunlu Dai, 2023. "Fueling sentinel node via reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant therapy," Nature Communications, Nature, vol. 14(1), pages 1-15, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:19:p:12480-:d:930025. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.